ARPA-H Puts Big Money Behind Custom Genetic Medicines
The Advanced Research Projects Agency for Health (ARPA-H) is committing up to $160 million to scientists building platforms for highly personalized genetic treatments, with a special focus on rare diseases in children. The goal is to move custom gene therapies from one-off, heroic efforts into something faster, more repeatable, and more widely available.
What the THRIVE program is trying to change
The funding comes through ARPA-H’s THRIVE program, short for Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines. Instead of developing a separate, bespoke drug and clinical trial for every single mutation, THRIVE backs teams that can build reusable systems for designing individualized genetic medicines, manufacturing them at smaller scale under consistent standards, and running umbrella clinical trials that treat multiple patients under one overarching protocol. The aim is to cut the time and cost needed to bring a tailored genetic medicine from concept to first‑in‑human treatment, especially for ultra‑rare disorders that only affect a handful of children worldwide.
Who is getting funding
Several leading hospitals, institutes and companies are receiving support under THRIVE, each focused on different types of rare conditions. Children’s Hospital of Philadelphia is building platforms for rare metabolic and blood disorders, building on its experience with a custom gene therapy for a single infant. The Broad Institute and partners such as The Jackson Laboratory and CHOP are working on personalized treatments for rare pediatric epilepsy. St. Jude Children’s Research Hospital and Massachusetts General Hospital are targeting bone marrow and blood vessel diseases, while Stanford University is focusing on severe genetic skin conditions like epidermolysis bullosa. Other awardees, including the Innovative Genomics Institute at UC Berkeley and AI‑driven biotech companies, are advancing custom gene editing for immune and heart disorders. Together, these projects span the brain, blood, bone marrow, vasculature, metabolism and skin, creating practical test cases for how personalized genetic medicines can move through design, regulation and trials in a more structured way.
Why this matters for patients and the industry
Families dealing with ultra‑rare genetic diseases often face a harsh reality: traditional drug development is too slow and costly for conditions that affect only a few patients. ARPA-H’s THRIVE program is meant to give those families a clearer path from diagnosis to potential treatment and to create blueprints that other rare disease groups can follow instead of starting over each time. It also pushes forward the underlying technology—gene editing tools, delivery systems, manufacturing methods and regulatory frameworks—that will be needed for many future precision medicines, not just the first wave. For biotech and health care more broadly, this funding signals that public investment is shifting toward platform infrastructure for genetic medicine, rather than only backing individual “miracle” drugs. If these platforms succeed, they could eventually support treatments for more common genetic conditions as well, extending the impact far beyond the initial focus on rare pediatric disease.
